Basic Information
| LncRNA/CircRNA Name | MIR22HG |
| Synonyms | MIR22HG, C17orf91 |
| Region | GRCh38_17:1711493-1717174 |
| Ensemble | ENSG00000186594 |
| Refseq | NR_028502 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR |
| Sample | hepatocellular carcinoma tissues, cell lines (SMMC-7721, Huh-7 and Hep3B cells) |
| Expression Pattern | down-regulated |
| Function Description | lncRNA MIR22HG expressed significantly lower in HCC tissues compared with non-tumorous tissues. Under-expression of lncRNAMIR22HG was an independent risk factor associated with the prognosis of patients with HCC.under-expression of MIR22HG was closely related to tumor encapsulation, microvascular invasion (MVI), and TNM stage. lncRNA MIR22HG under-expression was an independent risk factor associated with the prognosis of patients with HCC. |
| Pubmed ID | 29371967 |
| Year | 2017 |
| Title | Prognostic values of long non-coding RNA MIR22HG for patients with hepatocellular carcinoma after hepatectomy. |
External Links
| Links for MIR22HG | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |